Tag Archives: dolutegravir

July, 2018

26 July
Studies Show Two-Drug Regimen of Dolutegravir and Lamivudine Has Similar Efficacy to a Three-Drug Regimen in Treatment Naïve HIV Patients

LONDON–(BUSINESS WIRE)–ViiV Healthcare today presented at the 22nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 & 2 studies, assessing the safety and efficacy of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC) compared to a three-drug regimen of dolutegravir and two nucleoside …
Share

24 July
Gilead Announces Late-Stage Results for Investigational Triple-Combo Therapy for Treatment of HIV

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48-week results from two Phase 3 studies (Studies 1489 and 1490) evaluating the efficacy and safety of a fixed-dose combination of bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF), a …
Share

10 June
ViiV Announces FDA Approval to Lower the Weight Limit for Dolutegravir in Children with HIV

LONDON, June 10, 2016 /PRNewswire/ — Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral …
Share